Present and future of immunotherapy in melanoma
Omid Hamid
Director of Melanoma Therapeutics
The Angeles Clinic and Research Institute, Santa Monica
BRIDGE2017
-
Immunotherapy… and optimism
Bernard A. Fox
Laboratory of Molecular and Tumor Immunology
Oregon Health and Science University 
COMBI-AD: how does it change melanoma patient management?
Paolo Ascierto
UOC Oncologia Medica e Terapie Innovative
Istituto Nazionale Tumori Fondazione “G. Pascale”
BRAF+ metastatic melanoma: from low burden of disease to brain metastases
Reinhard Dummer
Department of Dermatology
University Hospital Zurich
Lymphadenectomy in sentinel node-positive melanoma: the reasons of yes
Merrick Ross
Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Lymphadenectomy in sentinel node-positive melanoma: the reasons of no
Jeffrey E. Gershenwald
Department of Surgical Oncology
University of Texas MD Anderson Cancer Center